TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult patients aged \>= 18 or =\< 65 years~* Patients with a diagnosis of asthma for a period of at least 1 year receiving daily treatment of ICS/LABA in a stable regimen for \>= 4 weeks~* Pre-bronchodilator FEV1 of \>= 50% and =\< 80% of the predicted normal value and an increase in FEV1 of 12% and \>= 200 ml during reversibility testing~Key Exclusion Criteria:~* Patients who have had an asthma exacerbation that required either treatment with systemic corticosteroids for at least 3 days, or an emergency room visit, or hospital treatment within 6 weeks prior to screening and patients with a history of life-threatening asthma attacks~* Patients who have had a respiratory tract infection within 4 weeks prior to screening.~* Patients who have smoked or inhaled tobacco products within the past 6 month of screening.~* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, and tuberculosis (unless tuberculosis is confirmed as no longer active by imaging).~* Patients on Maintenance Immunotherapy (desensitization) for allergies for at least 3 months prior to Run-in who are expected to change therapy throughout the course of the study.~* Patients who during the Run-in period are shown to be intolerable to LABA withdrawal.~* Patients who have discontinued LAMA therapy in the past (e.g. due to intolerance or perceived lack of efficacy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1(NVA237 50 ug/NVA237 25 ug/placebo) (Type: OTHER): Treatment sequence: NVA 237 50 ug, 25 ug and placebo
- 2(NVA237 50 ug/placebo/NVA237 25 ug) (Type: OTHER): Treatment sequence: NVA 237 50 ug, placebo and 25 ug
- 3 (NVA237 25 ug/NVA237 50 ug/placebo) (Type: OTHER): Treatment sequence: NVA237 25 ug, 50 ug and placebo
- 4 (NVA237 25 ug/placebo/NVA237 50 ug) (Type: OTHER): Treatment sequence: NVA 237 25 ug, placebo and 50 ug
- 5 (placebo/NVA237 50 ug/ NVA237 25 ug) (Type: OTHER): Treatment sequence: Placebo, NVA237 50 ug and 25 ug
- 6 (placebo/ NVA237 25 ug/NVA237 50 ug) (Type: OTHER): Treatment sequence: placebo, NVA237 25 ug and 50 ug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age between 6 and 59 months~* Weight ≥ 5 Kg~* P. falciparum infections (density threshold at inclusion between 2,000 and 200,000/µl)~* Fever (≥ 37.5°C) or history of fever in the previous 24 hours~Exclusion criteria:~* severe or complicated malaria~* reported hypersensitivities of the studied drugs~* serious concomitant febrile illness

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Artesunate and Amodiaquine (ASAQ) (Type: EXPERIMENTAL): children receiving fixed-dose combination of artesunate and amodiaquine
- Arthemeter and Lumefantrine (AL) (Type: ACTIVE_COMPARATOR): children receiving fixed-dose combination of arthemeter and lumefantrine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects, greater than 17 years of age~* Written informed consent has been obtained~* Ability to follow study instructions and likely to complete all required visits~* Written authorization for Use and Release of Health and Research Study Information has been obtained~* Subject meets the following criteria: clinical diagnosis of urinary urge incontinence with resistance to or intolerance of anticholinergic medication~* Anticholinergic medications allowed~* Willingness and ability to use self-catheterization if necessary~Exclusion Criteria:~* Uncontrolled clinically significant medical condition other than the condition under evaluation~* Known allergy or sensitivity to any of the components in the study medication~* Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study~* Concurrent participation in another investigational drug or device study~* Treatment with botulinum toxin of any serotype for urological condition prior to enrolment in study (if applicable)~* Any medical condition that may put the subject at increased risk with exposure to botulinum toxin A including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study~* Symptomatic urinary retention or post-void residual of \>200ml~* Anticoagulation therapy within 3 days of injection procedure~* Familial bleeding disorder~* UUI secondary to neurologic disease~* Myasthenia gravis~* Previous bladder pathology (e.g. transitional cell carcinoma)

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebos (Type: PLACEBO_COMPARATOR): Placebo injected into the detrusor at Day 1,
- Botulinum Toxins, Type A (Type: EXPERIMENTAL): Botulinum Toxins, Type A 100U injected into the detrusor at Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was \<60 ml/min on their most recent sample drawn within 1 month of the planned procedure~Exclusion Criteria:~* Circulatory shock for any reason, systolic blood pressure \<95 mm Hg~* Known acute renal failure~* End-stage renal disease requiring dialysis~* Intravascular administration of a contrast medium within the previous 10 days~* Anticipated re-administration of contrast medium within the following 6 days~* Inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure~* Primary intervention for acute infarction with ST elevation~* A procedure performed within 2 h of acute hospital admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Iloprost
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Providing Suboxone and PrEP Using Telemedicine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of self-report injection opioid use in the past 6 months~* Participate in SSPs,~* HIV negative~* Willing to take bup/nx and PrEP for 6 months~* No medical contraindications for these medications~* Not pregnant~* 18 years or older~* Not currently taking PrEP~* Not currently taking any form of MOUD~* History of sharing injection or drug preparation equipment or risk of sexual acquisition of HIV (such as engaging in sex work or men who have sex with men) in the past 6 months~Exclusion Criteria:~* Positive pregnancy test including during the course of the study~* Positive HIV test at enrollment~* Altered mental status in which participant cannot sign a consent form~* Renal insufficiency/failure~* Hepatitis B surface antigen positive~* Becoming incarcerated during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Medication and telemedicine follow up (Type: EXPERIMENTAL): All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be \>= 18 years of age~* meet Modified NY Criteria definition of ankylosing spondylitis (AS)~* have diagnosis of active AS based on protocol specified criteria~* inadequate response or intolerance to \>= 1 nonsteroidal antiinflammatory drug (NSAID)~* be able and willing to learn to self-administer subcutaneous (SC) injections~Exclusion Criteria:~* Active tuberculosis, listeriosis,or hepatitis B, or any history of hepatitis C~* History of demyelinating disease, multiple sclerosis, cancer, or lymphoproliferative disease~* Previous anti-tumor necrosis factor therapy~* Treatment with disease-modifying antirheumatic drugs (DMARDs - other than methotrexate, hydroxychloroquine, and sulfasalazine)~* Treatment with intra-articular corticosteroid joint injections within 4 weeks of study dosing~* Biologic or investigational therapy within 6 weeks of study dosing~* Treatment with intravenous (IV) antibiotics within 30 days of study dosing~* Treatment with oral antibiotics within 14 days of study dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Patients must have histologically confirmed hairy cell leukemia or hairy cell leukemia variant .with a need for therapy~* Patients must be Pseudomonas-immunotoxin naive~* Patients must have had at least 2 prior purine analogs, or at least 1 course of purine analog and 1 of either rituximab or BRAF inhibitor.~* Men or women age greater than or equal to 18 years.~* ECOG performance status less than or equal to 2.~* Patients must have adequate organ function~EXCLUSION CRITERIA~* Patients who have had chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to entering the study.~* Patients who are receiving any other investigational agents.~* Patients with known brain metastases should be excluded from this clinical trial~* Patients with clinically significant ophthalmologic findings during screening~* Pregnant or breastfeeding females.~* Positive for Hepatitis B core antibody or surface antigen unless the patient is on Lamivudine or Entecavir and Hepatitis B Viral DNA load is less than 2000 IU/mL.~* Active second malignancy requiring treatment other than minor resection of indolent cancers like basal cell and squamous skin cancers~* HIV-positive patients unless taking appropriate anti-HIV medications with a CD4 count of greater than 200.~* History of allogeneic bone marrow transplant.~* Patients with history of both thromboembolism and known congenital hypercoagulable conditions.~* Uncontrolled pulmonary infection, pulmonary edema.~* Adequate oxygen saturation~* Radioimmunotherapy within 2 years prior to enrollment in study.~* Adequate hematologic function~* Adequate lung function~* Patients with history of thrombotic microangiopathy or thrombotic microangiopathy / hemolytic uremic syndrome~* Patients with QTc interval (Friderica) elevation \> 500 msec based on at least 2 separate 12-lead ECGs~* Patient on high dose estrogen~* Patients with clinical evidence of disseminated intravascular coagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Moxetumomab pasudotox 40 µg/kg (Type: EXPERIMENTAL): Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline for the Treatment of Smokeless Tobacco

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible to participate if they:~1. Are at least 18 years of age~2. Have used ST daily for the past 12 months (regular user)~3. Identify ST as their primary tobacco product~4. Are in general good health (determined by medical history and screening physical examination)~5. Has provided written informed consent to participate~6. Are able to participate in all aspects of the study~Exclusion Criteria:~Individuals will be excluded from study participation if they:~1. Are currently (in previous 30 days) using other behavioral or pharmacologic tobacco cessation programs (i.e., behavioral therapy, nicotine replacement therapy, clonidine, bupropion SR, or doxepin)~2. Have self-reported current, untreated depression or a Beck Depression Inventory (BDI-II) Score of ≥ 20~3. Have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale);current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as potentially self-injurious act committed with at least some wish to die, as a result of act.)~4. History of psychosis or bipolar disorder~5. Are currently pregnant or lactating or is of childbearing potential and not willing to use any form of contraception~6. Have another member of their household already participating in this study~7. Are allergic to varenicline~8. Describe having a medical history of:~   * Unstable angina~  * Myocardial infarction within the past 3 months~  * Cardiac dysrhythmia other than medication-controlled atrial fibrillation or PSVT~  * Medically-treated or untreated hypertension with BP ≥ 200 systolic OR ≥ 100 diastolic~  * Have other medical or psychiatric conditions that would exclude the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- varenicline (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Niclosamide Role in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 diabetes mellitus at least 5 years ago~* Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary albumin creatinine ratio (UACR) \>30mg/g) despite treatment with maximum tolerated dose of ACE inhibitors for at least 8 weeks prior to the screening~* Hemoglobin A1c \> 6.5 % with regular use of insulin and/or oral glucose lowering agents~Exclusion Criteria:~* Type 1 diabetes mellitus~* Severe renal impairment (eGFR\< 30 mL/min/1.73 m2 at screening)~* Pregnant or lactating women~* Chronic heart failure~* Inflammatory or autoimmune disease~* History of kidney disease other than diabetic nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): Niclosamide tablets 1 gram once daily
- Control group (Type: PLACEBO_COMPARATOR): Lactose tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, Immunocompetent men and women in good health of any ethnic group~* History of recurrent episodes of genital herpes for at least 12 months~* Seropositive for Herpes Simplex Virus HSV Type 2~* Body Mass Index (BMI) between 18 and 35 kg/m2~Exclusion Criteria:~* Present episode of genital herpes~* Intake of systemic drug against HSV or any topical application against HSV within 7 days before randomization for the trial~* Intake of systemic corticosteroids, other immunomodulating agents or any investigational agent within 3 months before randomization for the trial~* Positive results in any of the virology tests for human immunodeficiency virus antibody (HIV-Ab), hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose regimen 1 (Type: EXPERIMENTAL): None
- Dose regimen 2 (Type: EXPERIMENTAL): None
- Dose regimen 3 (Type: EXPERIMENTAL): None
- Dose regimen 4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NAC +taVNS in IDM Who Are Poor Oral Feeders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants of diabetic mothers who are failing oral feeding, \>39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates~Exclusion Criteria:~* Unstable infants or those requiring positive pressure respiratory support~* Infants \<39 weeks gestation at enrollment~* Major unrepaired congenital anomalies or anomalies that limit feeding volumes~* Infants with cardiomyopathy~* Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 5 Months
- Healthy Volunteers: f

Study Arms:
- NAC + taVNS (Type: EXPERIMENTAL): NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bad Breath Response to Tongue Scraper and Rinses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult with threshold score of 2 on organoleptic halitosis evaluation~Exclusion Criteria:~* Taking another experimental drug, or antibiotic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chlorhexidine gluconate and scraper (Type: ACTIVE_COMPARATOR): The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
- Chlorine dioxide and scraper (Type: EXPERIMENTAL): The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 7-12 years~* IQ between 80-120.~* Gender: male or female~* Children with neurofibromatosis type 1 (according to the National Institutes of Health \[NIH\] 1988).~* Patients with school difficulties pointed out by parents or teachers~* Patients with attention difficulties as defined by anamnesis~Exclusion Criteria:~* IQ \> 120 or IQ \< 80~* Child depression~* Unwillingness to participate~* Patients with cerebral complication of neurofibromatosis type 1 (chiasma glioma, moya-moya) as detected by cerebral magnetic resonance imaging (MRI).~* Participation in another study

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete